Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has announced the approval of their new 2.5mg Rivaroxaban Tablets by China’s National Medical Products Administration, which, when combined with Aspirin, targets high-risk cardiovascular patients to reduce major events like heart attacks and strokes. This development marks the company as the third in China to receive approval for this product. The move is expected to significantly contribute to the company’s market presence in the cardiovascular and cerebrovascular drug segment and positively impact its financial performance.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
